Karolinska Development adds PharmNovo to its portfolio of companies
Author : Pankaj Singh | Published Date : 2022-07-05
Sweden-based life sciences investment company Karolinska Development has reportedly completed its investment in PharmNovo, thus making the clinical pharma company the tenth entity in Karolinska’s portfolio.
Karolinska Development has invested USD 1.9 million (SEK 20 million) in PharmNovo, through a new share issue that was led by Sciety, in total contributing around USD 6.4 million (67 million) to the company.
For those unaware, PharmNovo is a pharmaceutical company that specializes in developing effective and safe drugs for neuropathic pain, an area that has long struggled with a lack of treatment options.
The company is working on developing a novel treatment option, called PN6047, for a difficult-to-treat type of pain that usually turns into a chronic condition. This drug candidate has also effectively managed to lower nerve pain in animal models during preclinical studies.
PharmNovo is also looking to expand its reach into other areas including chronic cough, anxiety/depression, and migraine.
Meanwhile, Karolinska Development is a life sciences investment firm that emphasizes discovering breakthrough medical innovations in the Nordic region. The company focuses on investing in the development as well as the growth of firms that manage to transform these assets into commercial and successful products.
According to Karolinska Development CEO Viktor Drvota, PharmNovo’s drug candidate has demonstrated promising results during preclinical disease trials and has the potential to help several patients suffering from nerve pain.
Karolinska Development is known to have access to state-of-the-art medical innovations in the Nordic region. The investment firm intends to create companies surrounded by leading scientists, co-funded by international investors, and supported by an expert team of advisors.
Currently, the Sweden-based company has a portfolio of ten companies that focus on developing innovative treatment options for serious or life-threatening debilitating diseases. Karolinska Development now owns 13.7% in PharmNovo.
Source Credits –
About Author
Pankaj Singh . .
Endowed with a post graduate degree in management and finance, Pankaj Singh has been a part of the online content domain for quite a while. Having worked previously as a U.K. insurance underwriter for two years, he now writes articles for fractovia.org and other online portals. He can be contacted at- [email protected] | https://twitter.com/PankajSingh2605
Related News
Bayers new CEO initiates management job cuts to accelerate decision-making
Bayer newly appointed CEO, Bill Anderson, has reportedly unveiled plans to streamline the companys management structure in a bid to expedite decision-making processes. This marks the first step in a broader effort to transform the embattled German company, which has been under pressure from inv... Read More>>
Smurfit Kappa in Merger Talks with WestRock worth $19 Billion
Smurfit Kappa, a prominent player in the packaging industry, is reportedly engaged in merger discussions with its US counterpart, WestRock. This prospective merger has the potential to create a cardboard box-making powerhouse boasting a market value approaching $19 billion (€17.8 billion). Furt... Read More>>
RBC plans job cuts to take on anticipated economic softening
The Royal Bank of Canada is reportedly planning to reduce its workforce by approximately 1,800 jobs as part of cost-cutting measures, on account of the anticipated upcoming economic landscape. This decision comes after the country's largest bank surpassed analysts' predictions for the third ... Read More>>